Quick Answer
Cartesian Therapeutics, Inc. reported Total Revenue of $2.80 million for fiscal year 2025.
Cartesian Therapeutics, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $2.80M | -92.8% |
| 2024 | $38.91M | +49.6% |
| 2023 | $26.00M | -76.5% |
| 2022 | $110.78M | +30.2% |
| 2021 | $85.08M | +412.6% |
| 2020 | $16.60M | +148.6% |
| 2019 | $6.68M | +639.4% |
| 2018 | $903.0K | +336.2% |
| 2017 | $207.0K | -97.4% |
| 2016 | $8.08M | +34.5% |
| 2015 | $6.01M | +97.7% |
| 2014 | $3.04M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $452.0K | +16.8% | +51.7% |
| June 30, 2025 | $298.0K | -99.1% | -72.9% |
| March 31, 2025 | $1.10M | -81.2% | +184.2% |
| September 30, 2024 | $387.0K | -94.1% | -98.8% |
| June 30, 2024 | $33.45M | +537.2% | +472.7% |
| March 31, 2024 | $5.84M | -1.7% | -10.9% |
| September 30, 2023 | $6.55M | -68.4% | +24.8% |
| June 30, 2023 | $5.25M | -86.6% | -11.6% |
- Cartesian Therapeutics, Inc. showed a decrease of -92.8% in Total Revenue compared to the prior fiscal year.
- Over the 2014–2025 period, Cartesian Therapeutics, Inc.’s total revenue has declined by 8.0% (from $3.04 million to $2.80 million).
- The most recent figure is from Cartesian Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: